ALXOALX Oncology Holdings Inc.

$113M

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M-75.4% YoY

Gross Profit

$107,0009.1% margin

Operating Income

-$44M-3694.0% margin

Net Income

-$46M-3869.7% margin

EPS (Diluted)

$-1.28

Cash Flow

Operating Cash Flow

-$38M

Free Cash Flow

-$38M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$436M

Total Liabilities

$6M

Stockholders' Equity

$430M

Cash & Equivalents

$434M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$5M	-75.4%
Gross Profit	$107,000	$436,000	-75.5%
Operating Income	-$44M	-$19M	-127.6%
Net Income	-$46M	-$19M	-137.7%

ALXO FY 2020 Earnings — ALX Oncology Holdings Inc. Revenue & Financial Results | Market Cap Arena